Indication1
Hidradenitis Suppurativa (HS)
HUMIRA is indicated for the treatment of active moderate to severe
hidradenitis suppurativa (acne inversa) in adults and adolescents from
12 years of age with an inadequate response to conventional systemic
HS therapy.
For full Prescribing Information, please refer to the HUMIRA Summary
of Product Characteristics.
Important safety information1
Contraindications
Hypersensitivity to HUMIRA or any of the excipients, active
tuberculosis, or other severe infections, such as sepsis and
opportunistic infections, and moderate to severe heart failure (NYHA
class III/IV) are contraindications to the use of HUMIRA.
Serious Infection and Malignancy
Fatal and life-threatening infections (including sepsis, opportunistic
infections, and TB), HBV reactivation, and various malignancies
(including leukemia, lymphoma, and HSTCL) have also been reported with
use of HUMIRA.
Other Serious Adverse Events
Serious adverse reactions have been reported for HUMIRA.
TNF-antagonists, such as HUMIRA, affect the immune system and their
use may affect the body’s defense against infection and cancer.
Serious hematological, neurological, and autoimmune reactions have
been reported in patients treated with HUMIRA. These include rare
reports of pancytopenia, aplastic anemia, central and peripheral
demyelinating events, and reports of lupus, lupus-related conditions,
and Stevens-Johnson syndrome.
Pediatric Population
In general, the adverse events in pediatric patients treated with
HUMIRA were similar in frequency and type to those seen in adult
patients.
Vaccinations
It is recommended that pediatric patients, if possible, be brought up
to date with all immunizations in agreement with current immunization
guidelines prior to initiating HUMIRA therapy. Patients on HUMIRA may
receive concurrent vaccinations, except for live vaccines. The risks
and benefits of HUMIRA should be carefully considered prior to
initiating therapy.
For full prescribing information please
click
here
for the HUMIRA Summary of Product Characteristics.
Reference: 1. HUMIRA [Summary of Product Characteristics]
AbbVie Deutschland GmbH & Co. KG; October 2022
